Zhejiang Shengda Bio-Pharm Co., Ltd.

SHSE:603079 Stock Report

Market Cap: CN¥2.4b

Zhejiang Shengda Bio-Pharm Past Earnings Performance

Past criteria checks 0/6

Zhejiang Shengda Bio-Pharm's earnings have been declining at an average annual rate of -50.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 3% per year.

Key information

-50.1%

Earnings growth rate

-50.9%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate3.0%
Return on equity-1.9%
Net Margin-3.6%
Next Earnings Update28 Apr 2025

Recent past performance updates

Recent updates

Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 27% Share Price Plunge Could Signal Some Risk

Jan 12
Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 27% Share Price Plunge Could Signal Some Risk

Subdued Growth No Barrier To Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) With Shares Advancing 28%

Oct 28
Subdued Growth No Barrier To Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) With Shares Advancing 28%

What Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 27% Share Price Gain Is Not Telling You

Aug 08
What Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 27% Share Price Gain Is Not Telling You

Revenues Working Against Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) Share Price Following 26% Dive

Jun 12
Revenues Working Against Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) Share Price Following 26% Dive

Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 30% Dip In Price Shows Sentiment Is Matching Revenues

Apr 25
Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 30% Dip In Price Shows Sentiment Is Matching Revenues

Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Mar 08
Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Revenue & Expenses Breakdown

How Zhejiang Shengda Bio-Pharm makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:603079 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24792-298042
30 Jun 24749-317741
31 Mar 24743-547842
31 Dec 23727-547743
30 Sep 23746-186139
30 Jun 23751-157139
31 Mar 23722147339
31 Dec 22738317437
30 Sep 227465810640
30 Jun 227506810740
31 Mar 227837310439
31 Dec 217907610540
30 Sep 217806111037
30 Jun 218079411839
31 Mar 2186315813939
31 Dec 2086719714636
30 Sep 2081220314336
30 Jun 2071916412934
31 Mar 205949510628
31 Dec 19519479528
30 Sep 19512379325
30 Jun 19529419321
31 Mar 19496358722
31 Dec 18493458321
30 Sep 18494678323
30 Jun 18472686433
31 Mar 18510846727
31 Dec 17509737123
30 Sep 17471646814
31 Dec 16482611090
31 Dec 15536871450
31 Dec 1438144760

Quality Earnings: 603079 is currently unprofitable.

Growing Profit Margin: 603079 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 603079 is unprofitable, and losses have increased over the past 5 years at a rate of 50.1% per year.

Accelerating Growth: Unable to compare 603079's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 603079 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).


Return on Equity

High ROE: 603079 has a negative Return on Equity (-1.9%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/29 18:25
End of Day Share Price 2025/01/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zhejiang Shengda Bio-Pharm Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution